EpiPen Only Scratches The Surface Of The Drug-Price Crisis, JAMA Study Says - Forbes

ForbesEpiPen Only Scratches The Surface Of The Drug-Price Crisis, JAMA Study SaysForbesLast week, when the Mylan MYL -0.63% EpiPen pricing scandal was dominating the airwaves, the Journal of the American Medical Association (JAMA) published a study with a sobering bottom line: Per capita drug spending in the U.S. is $858 per year, vs.Our Children's Lives Depend on This Drug: A Mother's Plea to CEO After EpiPen Price Jumped 400%AlterNetMarkets and medicine: Behind the rising cost of prescription drugsPeople's Worldall 80 news articles »